Elsevier

Neuropharmacology

Volume 54, Issue 1, January 2008, Pages 129-140
Neuropharmacology

The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition

https://doi.org/10.1016/j.neuropharm.2007.08.011Get rights and content

Abstract

Converging evidence suggests that the endocannabinoid system is an important constituent of neuronal substrates involved in brain reward processes and emotional responses to stress. Here, we evaluated motivational effects of intravenously administered anandamide, an endogenous ligand for cannabinoid CB1-receptors, in Sprague–Dawley rats, using a place-conditioning procedure in which drugs abused by humans generally produce conditioned place preferences (reward). Anandamide (0.03–3 mg/kg intravenous) produced neither conditioned place preferences nor aversions. However, when rats were pre-treated with the fatty acid amide hydrolase (FAAH) inhibitor URB597 (cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester; 0.3 mg/kg intraperitoneal), which blocks anandamide's metabolic degradation, anandamide produced dose-related conditioned place aversions. In contrast, URB597 alone showed no motivational effects. Like URB597 plus anandamide, the synthetic CB1-receptor ligand WIN 55,212-2 (50–300 μg/kg, intravenous) produced dose-related conditioned place aversions. When anxiety-related effects of anandamide and URB597 were evaluated in a light/dark box, both a low anandamide dose (0.3 mg/kg) and URB597 (0.1 and 0.3 mg/kg) produced anxiolytic effects when given alone, but produced anxiogenic effects when combined. A higher dose of anandamide (3 mg/kg) produced anxiogenic effects and depressed locomotor activity when given alone and these effects were potentiated after URB597 treatment. Finally, anxiogenic effects of anandamide plus URB597 and development of place aversions with URB597 plus anandamide were prevented by the CB1-receptor antagonist AM251 (3 mg/kg intraperitoneal). Thus, additive interactions between the effects of anandamide on brain reward processes and on anxiety may account for its aversive effects when intravenously administered during FAAH inhibition with URB597.

Introduction

Converging evidence indicates that the endocannabinoid system is an important constituent of neuronal substrates involved in brain reward processes (Tanda et al., 1997, Tanda et al., 2000, Ledent et al., 1999, Justinova et al., 2005, Solinas et al., 2006) and emotional responses to stress (for review see: Valverde, 2005). However, little is known about direct effects of endogenous ligands for cannabinoid receptors on brain reward processes and emotional responses to stress. Anandamide (N-arachidonylethanolamide) was the first identified endogenous ligand for brain cannabinoid receptors (Devane et al., 1992). It is produced upon demand through activity-dependent cleavage of membrane lipid precursors, and is released from cells immediately after its production. After release, anandamide is rapidly eliminated through a two-step process involving transport into cells followed by intracellular hydrolysis to arachidonic acid and ethanolamide, catalyzed by fatty acid amide hydrolase (FAAH) (for review see: Piomelli, 2003). This rapid inactivation of anandamide has made study of its in vivo behavioral and neurochemical effects difficult. However, selective inhibitors of FAAH, such as URB597 (cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester) have recently been developed which can be used to magnify and prolong the effects of both endogenously released and exogenously administered anandamide (Kathuria et al., 2003, Lichtman et al., 2004, Mor et al., 2004, Fegley et al., 2005, Solinas et al., 2006, Solinas et al., 2007).

To date, there are only a few studies showing that endogenous cannabinoids such as anandamide interact and participate in the neuronal circuitry that signals rewarding events and controls emotional responses to stress. We recently demonstrated that intravenously administered anandamide is an effective reinforcer of drug-taking behavior in squirrel monkeys (Justinova et al., 2005) and produces THC-like discriminative effects in rats that are potentiated after FAAH inhibition by URB597 (Solinas et al., 2007). These effects of anandamide were blocked by the CB1-receptor antagonist rimonabant (SR141716). They were obtained with intravenous injection of anandamide, a route of administration that results in a more rapid onset and greater magnitude of effects than the more commonly used intraperitoneal route of administration (Smith et al., 1994). Intravenously administered anandamide also produces a rapid, short-lasting increase in extracellular levels of dopamine (DA) in the nucleus accumbens shell of rats, which is magnified and prolonged by URB597 and blocked by rimonabant and is a neurobiological marker of most drugs abused by humans (Solinas et al., 2006).

In this study, we first investigated the effects of intravenously administered anandamide with a place-conditioning paradigm, a procedure widely used in rodents to assess drug effects related to reward or aversion, that can be used to explore motivational brain reward processes related to drugs abused by humans (Mucha et al., 1982, Schechter and Calcagnetti, 1998, Tzschentke, 1998). Since anandamide is rapidly inactivated by FAAH enzymes, we also investigated the effects of intravenous anandamide after FAAH inhibition by URB597. For comparison, we examined the motivational effects of intravenous administration of the synthetic CB1-receptor agonist WIN 55,212-2 with the same place-conditioning procedure. In addition, we attempted to reverse any effects obtained in the place-conditioning experiments with AM251, a selective CB1-receptor antagonist (an analog of rimonabant with greater selectivity for CB1- over CB2-receptors; Gatley et al., 1996, Gatley et al., 1997).

It is known that the endocannabinoid system plays a modulatory role in emotional states such as anxiety and fear (Viveros et al., 2005). Several studies utilizing rodent models of anxiety or depression showed that FAAH inhibition produced anxiolytic-like effects (Kathuria et al., 2003, Patel and Hillard, 2006) and anti-depressant-like effects (Gobbi et al., 2005) in rats and mice, although these effects are not always found (Naidu et al., 2007). Also, the intra-dorsolateral periaqueductal injection of a low dose of anandamide has been reported to produce anxiolytic-like effects when assessed with the elevated plus-maze (Moreira et al., 2007). Consequently, in separate groups of animals, we next investigated the effects of intravenously administered anandamide alone and after FAAH inhibition by URB597 on anxiety-like responses at doses and combinations employed in the place-conditioning experiments. We used a light/dark test, a paradigm based on the innate aversion of rodents to brightly illuminated areas and on the spontaneous exploratory behavior of rodents in response to mild stressors, such as, novel environments and light (Crawley and Goodwin, 1980). Finally, to control for motor disturbances that anandamide or URB597 might induce, which could influence effects in the place-conditioning and light/dark box experiments, we investigated the effects of anandamide and URB597, alone and in combination, on spontaneous locomotor activity in an open-field test.

Section snippets

Animals

Subjects were male Sprague–Dawley rats (Charles River Laboratories, Inc., Wilmington, MA) weighing 300–325 g at the beginning of the experiments. They were individually housed in a temperature- and humidity-controlled room on a 12-h light/dark cycle. Experiments were conducted during the light phase. Food and water were available ad libitum and each animal was adapted to daily handling for 1 week before the start of experiments. Animals used in this study were maintained in facilities fully

Place-conditioning study

No significant baseline differences were found between the time spent by the different groups of rats in the two compartments of the place-conditioning apparatus during the pre-conditioning session before conditioning sessions were started.

Discussion

In the present study with Sprague–Dawley rats, the motivational effects of the endogenous cannabinoid receptor ligand anandamide in a place-conditioning procedure designed to measure rewarding or aversive effects of psychoactive drugs were compared with the emotional effects of anandamide in a light/dark box designed to measure anxiety. Intravenously administered anandamide, by itself, did not produce either conditioned place preferences or conditioned place aversions. However, when rats were

Acknowledgements

This research was supported by the Intramural Research Program of the NIH, National Institute on Drug Abuse, Department of Health and Human Services, by NIH Grants DA09158, DA7215, DA12413, and DA12447, by the Institute of Experimental Medicine, Hungarian Academy of Sciences, and by the Italian Ministry of University and Scientific Research (MIUR) and the Centre of Excellence on ‘Neurobiology of Dependence’.

References (47)

  • R.F. Mucha et al.

    Drug reinforcement studied by the use of place conditioning in rat

    Brain Res.

    (1982)
  • M.C. Saňudo-Peňa et al.

    Endogenous cannabinoids as an aversive or counter-rewarding system in the rat

    Neurosci. Lett.

    (1997)
  • M.D. Schechter et al.

    Continued trends in the conditioned place preference literature from 1992 to 1996, inclusive, with a cross-indexed bibliography

    Neurosci. Biobehav. Rev.

    (1998)
  • M.A. Smith et al.

    Social and environmental enrichment enhances sensitivity to the effects of kappa opioids: studies on antinociception, diuresis and conditioned place preference

    Pharmacol. Biochem. Behav.

    (2003)
  • K. Starowicz et al.

    Biochemistry and pharmacology of endovanilloids

    Pharmacol. Ther.

    (2007)
  • T.M. Tzschentke

    Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues

    Prog. Neurobiol.

    (1998)
  • M.P. Viveros et al.

    Endocannabinoid system and stress and anxiety responses

    Pharmacol. Biochem. Behav.

    (2005)
  • M. Beltramo et al.

    Functional role of high-affinity anandamide transport, as revealed by selective inhibition

    Science

    (1997)
  • M. Bortolato et al.

    Anxiolytic-like properties of the anandamide transport inhibitor AM404

    Neuropsychopharmacology

    (2006)
  • F. Chaperon et al.

    Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats

    Psychopharmacology

    (1998)
  • W.A. Devane et al.

    Isolation and structure of a brain constituent that binds to the cannabinoid receptor

    Science

    (1992)
  • L. Fattore et al.

    Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats

    Psychopharmacology

    (2001)
  • D. Fegley et al.

    Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation

    J. Pharmacol. Exp. Ther.

    (2005)
  • Cited by (0)

    View full text